The thesis gives a general review on agents used for neuromuscular junction blockage and their reversal in clinical settings. The thesis focuses mainly on the new drug sugammadex which opens a new category of neuromuscular junction block reversal due to unique mode of action. It has been approved by the FDA only recently (15th of December 2015), and in this thesis I compare various studies highlighting it's benefits and disadvantages.